Current treatment of metastatic bladder cancer and future directions

Amy Q. Lei, Liang Cheng, Chong Xian Pan

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Metastatic urothelial carcinoma portends a very poor long-term prognosis, with 5-year survival at approximately 5%. The overall survival of metastatic bladder cancer has not improved over the last 20 years. The first-line therapy is cisplatin-based chemotherapy with the response rate approximately 50%. Approximately 30-50% of the patients are unsuitable for cisplatin, and there is no standard of care for this patient population. There is no standard second-line treatment. Several signaling pathways are activated in bladder urothelial carcinoma, but no targeted therapy, either alone or in combination with conventional cytotoxic chemotherapy, has been shown to significantly improve the treatment outcomes. The future of metastatic urothelial carcinoma treatment lies in the ability to deliver personalized therapy. This area remains an active research field today.

Original languageEnglish
Pages (from-to)1851-1862
Number of pages12
JournalExpert Review of Anticancer Therapy
Volume11
Issue number12
DOIs
StatePublished - Dec 2011

Fingerprint

Urinary Bladder Neoplasms
Carcinoma
Cisplatin
Therapeutics
Drug Therapy
Survival
Standard of Care
Urinary Bladder
Direction compound
Research
Population

Keywords

  • chemotherapy
  • cisplatin
  • gemcitabine
  • metastatic urothelial carcinoma
  • targeted agents

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Current treatment of metastatic bladder cancer and future directions. / Lei, Amy Q.; Cheng, Liang; Pan, Chong Xian.

In: Expert Review of Anticancer Therapy, Vol. 11, No. 12, 12.2011, p. 1851-1862.

Research output: Contribution to journalArticle

Lei, Amy Q. ; Cheng, Liang ; Pan, Chong Xian. / Current treatment of metastatic bladder cancer and future directions. In: Expert Review of Anticancer Therapy. 2011 ; Vol. 11, No. 12. pp. 1851-1862.
@article{978003f3d03042de8cd0dfb0eb230683,
title = "Current treatment of metastatic bladder cancer and future directions",
abstract = "Metastatic urothelial carcinoma portends a very poor long-term prognosis, with 5-year survival at approximately 5{\%}. The overall survival of metastatic bladder cancer has not improved over the last 20 years. The first-line therapy is cisplatin-based chemotherapy with the response rate approximately 50{\%}. Approximately 30-50{\%} of the patients are unsuitable for cisplatin, and there is no standard of care for this patient population. There is no standard second-line treatment. Several signaling pathways are activated in bladder urothelial carcinoma, but no targeted therapy, either alone or in combination with conventional cytotoxic chemotherapy, has been shown to significantly improve the treatment outcomes. The future of metastatic urothelial carcinoma treatment lies in the ability to deliver personalized therapy. This area remains an active research field today.",
keywords = "chemotherapy, cisplatin, gemcitabine, metastatic urothelial carcinoma, targeted agents",
author = "Lei, {Amy Q.} and Liang Cheng and Pan, {Chong Xian}",
year = "2011",
month = "12",
doi = "10.1586/era.11.181",
language = "English",
volume = "11",
pages = "1851--1862",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Current treatment of metastatic bladder cancer and future directions

AU - Lei, Amy Q.

AU - Cheng, Liang

AU - Pan, Chong Xian

PY - 2011/12

Y1 - 2011/12

N2 - Metastatic urothelial carcinoma portends a very poor long-term prognosis, with 5-year survival at approximately 5%. The overall survival of metastatic bladder cancer has not improved over the last 20 years. The first-line therapy is cisplatin-based chemotherapy with the response rate approximately 50%. Approximately 30-50% of the patients are unsuitable for cisplatin, and there is no standard of care for this patient population. There is no standard second-line treatment. Several signaling pathways are activated in bladder urothelial carcinoma, but no targeted therapy, either alone or in combination with conventional cytotoxic chemotherapy, has been shown to significantly improve the treatment outcomes. The future of metastatic urothelial carcinoma treatment lies in the ability to deliver personalized therapy. This area remains an active research field today.

AB - Metastatic urothelial carcinoma portends a very poor long-term prognosis, with 5-year survival at approximately 5%. The overall survival of metastatic bladder cancer has not improved over the last 20 years. The first-line therapy is cisplatin-based chemotherapy with the response rate approximately 50%. Approximately 30-50% of the patients are unsuitable for cisplatin, and there is no standard of care for this patient population. There is no standard second-line treatment. Several signaling pathways are activated in bladder urothelial carcinoma, but no targeted therapy, either alone or in combination with conventional cytotoxic chemotherapy, has been shown to significantly improve the treatment outcomes. The future of metastatic urothelial carcinoma treatment lies in the ability to deliver personalized therapy. This area remains an active research field today.

KW - chemotherapy

KW - cisplatin

KW - gemcitabine

KW - metastatic urothelial carcinoma

KW - targeted agents

UR - http://www.scopus.com/inward/record.url?scp=82355164091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82355164091&partnerID=8YFLogxK

U2 - 10.1586/era.11.181

DO - 10.1586/era.11.181

M3 - Article

VL - 11

SP - 1851

EP - 1862

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 12

ER -